BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 7, 2014
View Archived Issues
Novartis presents data on novel, highly potent p53/Mdm2 inhibitor for cancer
Read More
Novel PARP inhibitor demonstrates potent antitumor activity in various tumor xenograft models
Read More
Encouraging efficacy and safety results for ISIS-SMNRx in infants with type I SMA
Read More
Cepham develops novel green coffee bean extract for weight management
Read More
Results of a phase II study of the PsA-TT vaccine in infants with meningococcal disease
Read More
Merck & Co. presents novel IRAK-4 inhibitors for cancer and other disorders
Read More
Children's Oncology Drug Alliance formed to develop neuroblastoma treatment
Read More
Auven Therapeutics signs license agreement with Mount Sinai
Read More
Lundbeck receives funding to research LRRK2-based biomarkers in Parkinson's disease
Read More
Sanofi reports achievements of first quarter 2014
Read More
Debiopharm and Yale sign license and research agreement for MIF inhibitors
Read More
Regeneron and Avalanche Biotechnologies enter gene therapy collaboration
Read More
Discovery of a novel small-molecule inhibitor for the treatment of malaria
Read More
Secutech International designs new agents for dermatological disorders
Read More
Novel thrombin inhibitors disclosed by Merck & Co. and Albany Molecular Research
Read More
Novel P2X7 receptor antagonists designed by Lundbeck
Read More
Astellas and Medivation receive FDA priority review for Xtandi sNDA
Read More
Low-dose suvorexant safe and effective in elderly and nonelderly adults with primary insomnia
Read More
MolMed reports data from phase III trial in malignant pleural mesothelioma
Read More
Cytomedix announces data from RECOVER-Stroke study
Read More
Yakult Honsha completes phase I study of resminostat in Japan
Read More
GeneSight Psychotropic test for antidepressant and antipsychotic treatment decisions expanded
Read More
FDA approves IND for Epidiolex in Dravet syndrome
Read More
Bayer and Merck & Co. sign consumer business deal and collaborate on sGC modulators
Read More
Immune Response BioPharma outlines plans for Remune
Read More